0      0

Coronary Artery Disease: The Beat Goes On

‐ Sep 21, 2013 10:30am

Coronary artery disease (CAD) is prevalent in the CKD population. The methods of diagnosis are the same; however, the treatment parameters and strategies differ. This session focuses on strategies to halt the progression of CAD and a pharmacological plan of care for the patient with CAD and CKD.

Contact hours available until 9/22/2015.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Conflict of Interest Disclosure:
Speaker(s) have no disclosures to declare.

Conference Committee Disclosures:
Dawn Koonkongsatian – Employee, Fresenius Medical Care
Kristin Larson – Employee, NxStage Medical
Denise Murcek – Employee, Fresenius Medical Care
Beth St. John - Employee, Fresenius Medical Care
Lucy Todd – Employee, Baxter Healthcare
Kyra Trappett – Employee, DaVita

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.

  • Summarize the impact of coronary artery disease (CAD) on the person with CKD.
  • Formulate treatment strategies to control the progression of CAD in the person with CKD.
  • Generate a pharmacologic treatment plan for the person with CAD and CKD.